https://scholars.lib.ntu.edu.tw/handle/123456789/582410
標題: | Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis | 作者: | Bieber, Thomas Simpson, Eric L Silverberg, Jonathan I Thaçi, Diamant Paul, Carle Pink, Andrew E Kataoka, Yoko CHIA-YU CHU DiBonaventura, Marco Rojo, Ricardo Antinew, Jeremias Ionita, Ileana Sinclair, Rodney Forman, Seth Zdybski, Jacek Biswas, Pinaki Malhotra, Bimal Zhang, Fan Valdez, Hernan |
公開日期: | 2021 | 卷: | 384 | 期: | 12 | 來源出版物: | The New England journal of medicine | 摘要: | The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. Data from trials comparing JAK1 inhibitors with monoclonal antibodies, such as dupilumab, that block interleukin-4 receptors are limited. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/582410 | ISSN: | 00284793 | DOI: | 10.1056/NEJMoa2019380 | SDG/關鍵字: | abrocitinib; dupilumab; placebo; abrocitinib; dupilumab; immunoglobulin A; interleukin 4 receptor alpha; Janus kinase 1; monoclonal antibody; placebo; protein kinase inhibitor; pyrimidine derivative; sulfonamide; adult; Article; atopic dermatitis; comparative effectiveness; controlled study; dose response; double blind procedure; drug dose comparison; drug safety; female; human; loading drug dose; major clinical study; male; nausea; phase 3 clinical trial; priority journal; prospective study; randomized controlled trial; skin pruritus; atopic dermatitis; blood; clinical trial; comparative study; multicenter study; oral drug administration; pruritus; severity of illness index; subcutaneous drug administration; Administration, Oral; Adult; Antibodies, Monoclonal, Humanized; Dermatitis, Atopic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Immunoglobulin A; Injections, Subcutaneous; Interleukin-4 Receptor alpha Subunit; Janus Kinase 1; Male; Placebos; Protein Kinase Inhibitors; Pruritus; Pyrimidines; Severity of Illness Index; Sulfonamides |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。